Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
G
Garimella, Tushar
Daiichi Sankyo Inc
075
:
Population Pharmacokinetics of Trastuzumab Deruxtecan (T-DXd) in Subjects With HER2-mutant & HER2-overexpressing Non-Small Cell Lung Cancer (NSCLC)
Tushar Garimella
Favorite
138
:
Exposure-Response Analyses of Efficacy & Safety of Trastuzumab Deruxtecan to Inform Dosing Recommendation in HER2-mutant Non-Small Cell Lung Cancer
Tushar Garimella
Favorite
Gebhart, Anthony
University of Florida
A007
:
Dose Optimization of Cefazolin in Adult Cardiac Surgery With Cardiopulmonary Bypass After Albumin Supplementation
Anthony Gebhart
Favorite
A007
:
Dose Optimization of Cefazolin in Adult Cardiac Surgery With Cardiopulmonary Bypass After Albumin Supplementation
Anthony Gebhart
Favorite
German, Polina
Cytokinetics, Incorporated
022
:
Clinical Evaluation of the Effect of Aficamten on QT/QTc Interval in Healthy Participants
Polina German
Favorite
Goh, Seoyoung
Seoul National University College of Medicine and Hospital
108
:
Pharmacokinetic Comparison of Ezetimibe/Rosuvastatin/Telmisartan Fixed-dose Combination vs Coadministration of Separate Treatments
Seoyoung Goh
Favorite
Gould, Errol
Enalare Therapeutics Inc.
105
:
ENA-001, a Novel BK-channel Blocker, Enhances Hypoxic Ventilatory Sensitivity and Alleviates Propofol-induced Respiratory Effects in Healthy Volunteers
Errol Gould
Favorite
148
:
The Mechanism of Action of an Innovative Respiratory Stimulant, ENA-001
Errol Gould
Favorite
Goyal, Navin
Janssen Research & Development, LLC, a Johnson & Johnson Co
052
:
Nipocalimab Pharmacokinetic/Pharmacodynamic & Exposure-Response Modeling in Pregnancies at Risk for Early-onset Severe (EOS) HDFN
Navin Goyal
Favorite
060
:
Pharmacokinetic Modeling of the IRF5 Antisense Oligonucleotide JNJ-66525433 & IRF5 mRNA Expression in Healthy Individuals
Navin Goyal
Favorite
Gupta, Vipul
Schrodinger Inc.
076
:
First-in-Human Phase 1 SAD, MAD, Food Effect & DDI Study of SGR-1505, a Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 Inhibitor, in Healthy Volunteers
Vipul Gupta
Favorite
140
:
Pharmacokinetic-Pharmacodynamic Analysis of Cytokines in First-in-Human Phase 1 Dose Escalation Study of the MALT-1 Inhibitor, SGR-1505, in Healthy Volunteers
Vipul Gupta
Favorite
